Soluble Receptor for Advanced Glycation End Products (sRAGE) in Non-Diabetic Hemodialysis Patients and Chronic Kidney Disease

Background: Advanced glycation endproducts (AGEs) exert part of their cellular effects by binding to a receptor, named receptor for AGEs (RAGE). The soluble form of this receptor (sRAGE) has been shown to have an athero-protective role.Aim of Work: The aim of this study is to demonstrate the relationship of sRAGE to renal function in patients with chronic kidney disease (CKD) and hemodialysis patients (HD), and to correlate its serum levels with arterial atherosclerosis by the measurement of carotid intima media thickness (IMT). Material and Methods: A cross sectional study including 20 hemodialysis patients, 20 chronic kidney disease patients and 10 controls. Soluble RAGE was measured using an Elisa kit and carotid intima media thickness was measured using ultrasonographic scanning of the carotid artery.Results: Serum sRAGE levels were significantly higher in group 1 compared to group 2 3 (mean ± SD was 3435.3pg/ ml ± 204.5 in group (1) vs 1613.1pg/ml ± 114.1 in group (2) 607.4pg/ml ± 82.6 in group (3) with p-value 0.001, and in group 2 compared to group 3 with p = 0.002. Significant correlation was found between serum sRAGE levels and serum creatinine, but no significant correlation could be detected to CRP level, Carotid artery (IMT) or cholesterol in both patient groups.Conclusions: SRAGE levels are increased in patients with decreased renal function, mainly patients with end-stage renal disease. No significant correlation could be detected between serum sRAGE levels and Carotid artery (IMT) or cholesterol in both patient groups.